WATCHMAN™装置植入3年未完全内皮化的病例报告
本文报告一例73岁男性在WATCHMAN™左心耳封堵装置植入3年后因症状性重度二尖瓣反流行二尖瓣修复术,术中见装置未内皮化,遂移除装置并在瓣膜修复后结扎左心耳。作者指出左心耳封堵术后不完全内皮化的长期发生率与临床意义有待研究,术后及围术期抗血小板与抗凝方案需重新评估。
要点
- 动物研究显示装置3个月内皮化,但本例人植入3年后仍未内皮化。
- 装置内皮化前具有致血栓性,需依赖抗血小板治疗。
- 不完全内皮化的长期发生率与临床意义尚待研究,抗栓方案需重新评估。
核心结论
- WATCHMAN™装置植入3年仍可能未内皮化,提示术后抗血小板与抗凝方案及左心耳封堵策略需重新评估。
研究设计与样本
- 单例病例报告:73岁男性,WATCHMAN™植入3年后因症状性重度二尖瓣反流行二尖瓣修复术。
主要发现
- 术中见WATCHMAN™装置未内皮化,移除装置并于二尖瓣修复后结扎左心耳。
- 装置内皮化前具有致血栓性,双联抗血小板治疗时程基于动物研究3个月内皮化的结果。
临床怎么用
- 在心外手术中应探查既往植入的左心耳封堵装置内皮化状态,必要时移除并结扎左心耳。
- 需重新评估左心耳封堵术后及围术期抗血小板与抗凝方案,并考虑胸腔镜心外膜左心耳夹闭的潜在作用。
局限性
- 仅为单例病例报告,不能推断不完全内皮化的发生率或临床意义。
- 原文未报告随访时间、影像学细节及抗栓方案的具体疗程。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
WATCHMAN™ is a left atrial appendage (LAA) occlusion device used to prevent thromboembolism in patients with atrial fibrillation. Endothelialization of the device is required to completely occlude the LAA. Prior to endothelialization, the device is thrombogenic. The duration of dual-antiplatelet therapy after device insertion is based on animal studies demonstrating endothelialization at 3 months. A 73-year-old man presented with symptomatic severe mitral regurgitation 3 years after the WATCHMAN device was implanted. During mitral valve repair, we found that the WATCHMAN device was not endothelialized. The device was removed and the LAA was ligated after repair of the mitral valve. The long-term incidence and clinical significance of incomplete endothelialization after LAA-occlusion must be investigated. Postimplantation and perioperative antiplatelet and anticoagulation protocols require re-evaluation. The potential role of thoracoscopic epicardial LAA clipping must be considered.
引用
- McIvor F, Wall D. Who watches the WATCHMAN™? A case of incomplete endothelialization at 3 years after device implantation. Eur J Cardiothorac Surg. 2019. PMID: 31106326. doi:10.1093/ejcts/ezz135
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。